跳到正文
原文
The Lancet Oncology· Ian F Tannock, Michael Brundage, Christopher M Booth, Nathan I Cherny, Corneel Coens, Elizabeth A Eisenhauer, Jan Geissler, Johannes M Giesinger, Bishal Gyawali, Sjoukje F Oosting, Gregory R Pond, Jaap C Reijneveld, Enrique Soto-Perez-de-Celis, Michelle Tregear, Winette T A van der Graaf, Brooke E Wilson, Madeline L Pe·· 2026-09-30AI 评分25

Common-Sense Oncology 和 EORTC 关于辅助系统治疗临床试验中健康相关生活质量报告的建议

[Policy Review] Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer

AI 导读

旨在治愈癌症的辅助系统治疗可能降低患者健康相关生活质量(HRQOL),需权衡其对复发风险的减少。由于许多辅助疗法仅带来微小的复发或总生存率改善,治疗相关副作用的严重性和持续时间及其对患者功能和整体HRQOL的影响对临床决策至关重要。

来源:The Lancet Oncology · thelancet.com